Significant biological role of Sp1 transactivation in multiple myeloma

Mariateresa Fulciniti¹,², Samir Amin¹, Puru Nanjappa¹, Scott Rodig¹, Rao Prabhala², Cheng Li¹, Stephane Minvielle³, Yu-tzu Tai¹, Pierfrancesco Tassone⁴, Herve Avet-Loiseau³, Teru Hideshima¹, Kenneth C. Anderson¹, and Nikhil C. Munshi¹,²

¹Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA 02115; ²VA Boston Healthcare System, Harvard Medical School, Boston, MA 02115; ³Centre Hospitalier Universitaire de Nantes, IRCNA, Laboratoire d’Hématologie, Nantes, France ⁴University of “Magna Græcia”, Catanzaro 88100, Italy.

Running title: Sp1 activity Inhibition as MM therapeutic target.

Correspondence may be addressed to:

Nikhil C. Munshi, MD

Dana Farber Cancer Institute

44 Binney Street, M1B28

Boston, MA 02115

e-mail: Nikhil_Munshi@dfci.harvard.edu
Abstract

Purpose: The transcription factor Sp1 controls number of cellular processes by regulating the expression of critical cell cycle, differentiation and apoptosis-related genes containing proximal GC/GT-rich promoter elements. We here provide both experimental and clinical evidence that Sp1 plays an important regulatory role in MM cell growth and survival.

Experimental design: We have investigated the functional Sp1 activity in MM cells using a plasmid with renilla luciferase reporter gene driven by Sp1-responsive promoter. We have also used both SiRNA and ShRNA-mediated Sp1 knock-down to investigate the growth and survival effects of Sp1 on MM cells, and further investigated the anti-MM activity of Terameprocol (TMP), a small molecule which specifically competes with Sp1-DNA binding in vitro and in vivo.

Results: We have confirmed high Sp1 activity in MM cells which is further induced by adhesion to bone marrow stromal cells (BMSC). Sp1 knock down decreases MM cell proliferation and induces apoptosis. Sp1-DNA binding inhibition by TMP inhibits MM cell growth both in vitro and in vivo, inducing caspase 9-dependent apoptosis and overcoming the protective effects of BMSCs.

Conclusions: Our results demonstrate Sp1 as an important transcription factor in myeloma that can be therapeutically targeted for clinical application by TMP.

Statement of translational relevance

The transcription factor Sp1 affects growth and metastatic potential of tumor cells. In MM, key genes such as NF-k p65, IGF-IR, VEGF, and IL-6 contain proximal GC-rich promoter sequences, and their interactions with Sp proteins are critical for their expression. Here we show that Sp1 plays an important role in myeloma cell growth and survival. Importantly, Sp1-specific inhibitor is able to induce tumor apoptosis in murine models of MM. Thus inhibition of Sp1 may be an attractive therapeutic modality in MM, alone or in combination with other agents.
Introduction

Specificity Protein 1 (Sp1) and other Sp and Kruppel-like factor (KLF) proteins are members of a family of transcription factors which bind GC/GT-rich promoter elements through three C2H2-type zinc fingers that are present at their C-terminal domains (1).

Sp1 regulates gene expression both by direct interaction with promoter elements as well as via protein-protein interactions or interplay with other transcription factors, such as Ets-1, c-myc, c-Jun, Stat1, and Egr-1, and/or components of the basal transcriptional machinery (2). Sp1 has been also linked to chromatin remodeling through interactions with chromatin-modifying factors such as p300 (3) and histone deacetylases (HDACs) (4).

Although Sp1 has been considered as a ubiquitous transcription factor, increasing evidence suggests that it plays a major role in regulating expression of cell differentiation, cell cycle and apoptosis related genes affecting cellular growth (5). Sp1 levels and/or activity are increased in multiple cancers including breast (6), colon (7), gastric (8), pancreatic (9-12), and thyroid cancer (13) as compared with normal tissues. Elevated Sp1 expression is inversely correlated with the survival of patients with gastric cancer (14) and identifies advanced stage tumors and predicts a poor clinical outcome in primary pancreatic adenocarcinoma (12). On the other hand, interference of Sp1 activity has been shown to suppress tumor cell growth (15, 16) as well as tumor formation in athymic mice (6, 17) suggesting that Sp1 plays a central regulatory role in controlling number of pathways of tumor development and progression and thus may be an attractive therapeutic target.

Sp1 could contribute to transformation via regulation of the expression of Sp1-responsive genes including those supporting cell growth (c-jun, Raf, cyclins, E2F1, TGF-β, IEX-1 and TCL1)(18, 19) and apoptosis (Bcl-2, Survivin)(5, 20). Sp1 also regulates genes involved in angiogenesis and metastasis, including VEGF, uPA (21), PSA, and MT1-MMP (22). Enhanced Sp1 activity is related to both increased Sp1 gene expression and its posttranslational modification; for example, Sp1 phosphorylation regulates target genes in both positive and negative directions (23, 24).

Although Sp1 has been described to modulate autocrine IL-6 secretion by MM cells affecting its growth (25), its role in MM pathobiology remains unexplored. The promoter of several genes such as NF-kB p65, IGF-IR, VEGF, hTERT and IL-6 that regulate MM cell growth, cell cycle progression, survival and apoptosis contains proximal GC-rich promoter
sequences that interact with Sp1 protein for their optimal expression (25-28). In addition, the same kinase pathways that have been shown to increase Sp1 phosphorylation and the transactivation of target genes (21, 22) are also known to mediate proliferation, survival, drug resistance, and migration (ERK, Jak/STAT, PI3K/Akt, and PKC signaling cascades, respectively) in MM.

Here we report significant role of Sp1 in myeloma cell growth and survival. Our results suggest that Sp1 activity can be therapeutically targeted for clinical application in MM.
Materials and Methods

Cells. Bone marrow mononuclear cells (BMMNCs) and primary MM cells from BM aspirates from MM patients following informed consent and Dana-Farber Cancer Institute IRB approval were isolated using Ficoll-Hypaque density gradient sedimentation. MM patient cells were separated from BM samples by antibody-mediated positive selection using anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotech, Gladbach, Germany). BMSC were established as previously described (29). MM cell lines were cultured in RPMI 1640 (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS). The IL-6 dependent MM cell lines INA-6 (kindly provided from Dr. R. Burger, University of Kiel, Germany) were cultured presence of 2.5 ng/mL rhIL-6 (R&D Systems, Minneapolis, MN).

Reagents. TMP was synthesized and dissolved in CPE as previously described (30).

Cell proliferation assay. MM cell proliferation was measured by [3H]-thymidine (Perkin-Elmer, Boston, MA) incorporation assay as previously described (29).

Bromodesoxyuridine (BrdU) staining. The proportion of myeloma cells in S-phase was determined by incorporation of BrdU. 1 × 10^6 MM cells were exposed to 10 µg/ml of BrdU for 30 min. The cells were then harvested and stained with FITC anti-BrdU Ab and 7-AAD using a BrdU Flow Kit (BD Bioscience Pharmingen) according to the manufacturer’s directions. Cells were analyzed by flow cytometric analysis with a Becton-Dickinson FACScan flow cytometer.

Apoptosis assay. Apoptosis was evaluated by flow cytometric analysis following Annexin-V and propidium iodide (PI) staining.

Sp1 binding activity. The Sp1 binding activity was analyzed using the Transcription Factor ELISA kit, a DNA-binding enzyme-linked immunosorbent assay (ELISA)–based assay (Panomics). Sp1 transcription factor binding to its consensus sequence on the plate-bound oligonucleotide was studied from nuclear extracts, following the manufacturer's procedure. Briefly, nuclear proteins were extracted with a Nuclear Extraction kit (Panomics) and quantified using the Bio-Rad Protein Assay kit (Bio-Rad). A total of 15 µg of nuclear protein from each treatment were analyzed. Sp1 antibody was used as primary antibody and anti-rabbit IgG horseradish peroxidase was used as secondary antibody. The absorbance was measured at a wavelength of 450 nm on a spectrophotometer.

Promoter activity assay. The Sp1 promoter reporter constructs was purchased from Sabiosciences. To examine transcriptional regulation of the Sp1 promoter by TMP, MM cells
were transiently transfected with 1 µg of Sp1 reporter plasmid or empty vector control by electroporation using AMAXA technology according to the manufacturer's instructions. Luciferase assays were performed with a Luminoskan Ascent 2.4 luminometer and the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase values were normalized to Renilla luciferase activity and were either expressed as relative luciferase units (RLU) or as mean ‘fold induction’.

Sp1 knock down:

siRNA. RNA interference was performed using the TranSilent Human Sp1 siRNA (Panomics, Inc., Redwood, CA) following the manufacturer’s instructions. Nontargeting scrambled negative control siRNA (Panomics, Inc., Redwood, CA) was used as negative control. Briefly, U266 and OPM2 cells were seeded to 80% confluence in six-well plates in triplicate and transiently transfected with 2 µM of Sp1 siRNA by electroporation using AMAXA technology.

shRNA. Lentiviral shRNA were used to knockdown Sp1 expression in MM cells. Scrambled and Sp1 pLKO shRNA vectors were provided by Dr. William Hahn (Dana-Farber Cancer Institute). Recombinant lentivirus was produced by transient infection of 293T cells following a standard protocol, as previously described (31).

Immunoblotting. Whole cell lysates, nuclear extracts or cytosolic fractions of lysates (30 µg) were subjected to SDS-PAGE using “Precast Gel” (Bio-Rad Laboratore, Melville, NY), transferred to a nitrocellulose membrane (Bio-Rad), and immunoblotted with anti -Sp1 (Abcam) -Survivin, -Caspase-3,-7,-8,-9, -PARP (Cell Signaling Technology, Danvers, MA) antibodies (Abs). After incubating with secondary Ab, membranes were developed by enhanced chemiluminescence (GE Healthcare, Piscataway, NJ).

In vivo study:

s.c. model. The in vivo efficacy of TMP was tested in a murine xenograft model of MM using U266, MM1S or OPM2 MM cell lines injected s.c. in SCID mice. Following detection of tumor, mice were treated with either vehicle or TMP (50 mg/Kg) s.c. for 5 consecutive days/week for 2 weeks. Tumor growth was measured as previously described (32). Excised tumors from mice were immediately fixed and stored in 10% formalin. The fixed tissue was then dehydrated through a series of graded alcohols and xylene and embedded in paraffin. The paraffin tissue blocks were thin sectioned and stained for microscopy with H&E or analyzed by immunocytochemical methods for Ki67, tunel and caspase-3. The survivin level analysis was
performed following staining with a combination of anti-CD138 and anti-survivin antibody. Appropriate immunofluorescent secondary antibodies were applied along with the nuclear dye DAPI. The tissue sections were imaged and the relative amount of survivin localized within tumor-cell nuclear compartment was determined using an automatated quantitation of antigen expression (AQUA) analysis. The data reflects the results of 12 fields imaged at 200x magnification per tumor.

**SCID-hu model.** Six- to eight week old male CB-17 severe combined immunodeficient (SCID) mice (Taconic, Germantown, NY) were housed and monitored in our Animal Research Facility. All experimental procedures and protocols had been approved by the Institutional Animal Care and Use Committee (VA Boston Healthcare System). Human fetal bone grafts were s.c. implanted into SCID mice (SCID-hu) as previously described. Four weeks following bone implantation, $3 \times 10^6$ INA-6 MM cells were injected directly into the human bone implant. Mouse sera were serially monitored for shuIL-6R by ELISA (R&D Systems, Inc., Minneapolis, MN).

**Statistical analysis.** The statistical significance of differences was analyzed using the t test; differences were considered significant when $P \leq 0.05$. Tumor growth inhibition and Kaplan–Meier survival analysis were determined using the Graphpad analysis software.
Results

High Sp1 protein expression and activity in MM. Sp1 is ubiquitously expressed in cells; however, its nuclear localization is important for functional activity. We first evaluated nuclear Sp1 protein levels in MM cell lines and normal PBMC. All MM cell lines had high nuclear Sp1 expression while normal PBMCs had predominantly cytoplasmic Sp1 with relatively small amount of nuclear localization (Fig. 1A-B). We further confirmed increased Sp1 nuclear levels and binding activity in MM cells compared to PBMC and BMSC using an ELISA-based Sp1 binding assay (Fig. 1C).

As activation of Akt and Erk signaling pathways induces nuclear translocation and activation of Sp1 (21) and these pathways are activated in MM cells by their interaction with BM microenvironment, we investigated whether the presence of BMSC could modulate Sp1 activity in MM cells. Using a plasmid containing renilla luciferase reporter gene driven by Sp1-responsive promoter, we observed that the interaction between MM cells and BMSC significantly induced the transcriptional activity of Sp1 in MM cells (Fig. 1D). This increase was completely abrogated by the ERK pathway inhibitor U0126 but not by the AKT inhibitor LY29004.

Sp1 knock-down decreases MM cell proliferation. We have further evaluated the role of Sp1 in MM by analyzing the effect of Sp1 knockdown on MM cell growth and survival. We first knocked down endogenous Sp1 by RNA interference in U266 MM cells. Western blot and ELISA-based analysis confirmed reduction in both cytoplasmic and nuclear levels of Sp1 protein following transient transfection of MM cells with Sp1 siRNA compared with cells transfected with control scrambled siRNA (Fig. 2A-B). Interestingly, we also found that reduction of Sp1 levels was associated with inhibition of MM cell proliferation (Fig. 2C) and significant changes in the cell cycle with increase in G2/M and decrease in S phases (Fig. 2D). We have confirmed these data using OPM2 cells (Fig. 2E). Additionally, using 5 different Sp1-specific shRNA constructs, we have confirmed the inhibitory effect of Sp1 knockdown on MM1S cell proliferation and Sp1 activity (Fig. 2F). The cell populations with the largest reduction in Sp1 protein (shRNA #2, #3, #5) showed the greatest cell growth inhibition, compared to the vector control cell lines. Two of the Sp1 shRNAs that do not efficiently knock down Sp1 has less or no effect on phenotype, indirectly but reliably confirming the specificity of the effect. We used
Inhibition of Sp1 activity by a chemical inhibitor induces MM cell growth arrest and apoptosis via caspases activation and reduction in survivin protein level.

Our next approach was based on selective interference of Sp1-mediated transactivation of genes with TMP, a lignan tetra-O-methyl nordihydroguaiaretic acid derivative, which has been shown to specifically bind to Sp1-specific DNA binding domains within the responsive gene promoter regions and interfere with the transcription of these Sp1-controlled genes (33-36). We have confirmed decreased DNA binding activity of Sp1 by TMP as assessed by ELISA-based Sp1 binding assay (Fig. 3A), along with decreased basal and BMSC-induced Sp1 transcriptional activity (Fig. 3B). Importantly, Sp1 protein level in MM cells was not affected by 24 hours TMP treatment (Fig. 3C), suggesting that the modulation of Sp1 binding activity by TMP was not due to change of Sp1 protein level. We have confirmed these data using an additional MM cell line, observing that longer exposure to TMP led to decrease Sp1 protein expression (supplemental Figure 1).

We next assessed the effect of the TMP-mediated inhibition of Sp1 binding activity on MM cell growth. We have examined the effect of the Sp1 inhibitor in MM cell lines with constitutive activation of the canonical and/or non-canonical NFkB pathways. TMP significantly inhibited DNA synthesis in all MM cell lines tested in a dose-dependent fashion (Fig 3D). In the most sensitive cell line the IC50 is in the range of 1-10 uM, while in the less sensitive cell lines the IC50 is in the range of 10-20 uM for a 24 hours period of treatment. Importantly, TMP inhibited proliferation of primary patient MM cells overcoming the MM growth promoting effect of BMSC (Fig. 3E) without affecting the viability of the normal BMSC (Fig. 3F).

Following exposure to TMP, we have also observed increase in G2/M and decrease in S phases of the cell cycle (Fig. 4A), as well as late induction of apoptotic cell death (Fig. 4B) in MM cells. We have further observed activation of the mitochondrial apoptotic pathway by TMP via activation of caspase-9, -3 and -7 and PARP cleavage while caspase-8 was not activated (Fig. 4C). Change in the protein expression of survivin, a known anti-apoptotic gene transcriptionally regulated by Sp1 (37), was confirmed following TMP treatment (Fig. 4C). Since caspase activation is a relatively late event, the reduction in survivin protein level during TMP-induced apoptosis appears to be an early event not mediated by caspase-dependent pathway. We have
also observed decrease in cyclin-dependent kinase 1 (cdk1), a Sp1-regulated and cell cycle-controlling gene following exposure to TMP (data not shown). Finally, since Sp1 is an important regulator of the expression of important angiogenic factors, including VEGF which is believed to play a critical role in myeloma angiogenesis, we aimed to evaluate if inhibition of Sp1 binding activity by TMP impairs VEGF production by MM cells. As shown in supplemental Fig 2, six hours exposure to TMP were sufficient to decrease VEGF levels in the culture supernatant of both MM1S and U266.

Thus, the antitumor activity of TMP may result, at least in part, from suppression of Sp1 activity and the consequent down-regulation of downstream targets that are key to cell growth, apoptosis and angiogenesis.

**TMP inhibits MM cell growth and prolongs survival *in vivo* in a xenograft murine model of MM.** Next, we investigated the anti-MM effect of Sp1 inhibition by TMP *in vivo* in 3 different murine xenograft models of human myeloma as well as in the SCID-hu model of human myeloma. In the xenograft models, we injected subcutaneously (s.c.) 3 different MM cell lines, U266, OPM2 and MM1S in SCID mice. Following detection of tumor, mice were treated with either 50 mg/kg TMP or placebo s.c. daily for 3 weeks. Tumors were measured in two perpendicular dimensions once every 3 days. Treatment with TMP, compared to vehicle alone, significantly inhibited MM tumor growth in all 3 murine models of MM (Fig. 5A). As seen in Fig. 5B, treatment with TMP also significantly prolonged survival in treated animals compared to control (p=0.017); the median overall survival was 18 days in the control group and 28 days in the TMP-treated group. TMP-related toxicity was not observed in mice, as determined by daily evaluation of activity and overall body weight change during the course of treatment. Histological examinations of tumor retrieved from MM1S-bearing mice confirmed decreased proliferation (as highlighted by Ki-67 staining), significant tumor cell apoptosis (caspase-3 and TUNEL staining) (Fig. 5C) as well as decreased expression of Survivin (Fig. 5D) following TMP treatment in vivo.

In the SCID-hu model, 4 weeks after implanting human fetal bone in mice, human myeloma cells are injected in the bone and sIL-6R levels are measured in murine blood as a marker of myeloma tumor growth. SCID-hu mice were injected with TMP five times a week for 3 weeks after first detection of shuIL-6R in mice. We observed significant antitumor activity of
TMP as measured by shuIL-6R levels in murine blood, suggesting MM cell growth inhibitory effects of TMP (Fig. 5E).

**Discussion**

Alteration in expression and function of transcription factors has been frequently associated with neoplastic transformation. In this study, we provide experimental evidence that Sp1, a transcription factor that controls number of cellular processes, plays an important regulatory role in MM cell growth and survival.

Although Sp1 is ubiquitously expressed, its nuclear localization, observed in MM is functionally important. We have confirmed high Sp1 activity in MM cells both by demonstrating increased DNA binding as well as increased Sp1-responsive promoter activity measured by luciferase reporter assay. We here further confirmed effect of Sp1 on MM cell growth by using both SiRNA and ShRNA-mediated Sp1 knock-down using multiple constructs.

MM cell-BMSC interaction induces transcription and secretion of cytokines and growth factors that in turn confer proliferation and survival of MM cells. We here observed that this interaction leads to Sp1 activation; and inhibition of Sp1 activity by TMP led to suppression of MM-BMSC interaction-mediated growth of MM cells. Moreover, MM-BMSC interaction induces the activation of several signaling pathways, which in turn lead to Sp1 phosphorylation and transactivation of target genes. In line with these observations we report that the MM-BMSC-induced increase in both DNA binding and Sp1 transcriptional activity in MM cells was completely abrogated by inhibition of ERK pathway.

Compounds, such as TMP, able to disrupt the interaction between Sp1 and GC-rich motifs inhibit Sp1 activity. We have confirmed specific inhibition of both Sp1 binding and transcriptional activity in MM cells by TMP, including in the context of MM-BMSC interaction, without direct effect on Sp1 protein expression. Along with inhibition of Sp1 activity, we observed both *in vitro* and *in vivo* anti-myeloma effect of TMP. Importantly, there was no significant synergistic effect when MM cells transfected with Sp1 siRNA were treated with TMP (data not shown), confirming specificity of TMP’s mechanism of action. These results provide the rationale to evaluate efficacy of TMP in MM. TMP is currently in phase I/II clinical development for the treatment of glioma, treatment-refractory solid tumors and cervical dysplasia (38).

Altered survivin expression may be one of the mechanisms by which Sp1 may affect MM
cell survival. Survivin is an inhibitor of apoptosis and a possible modulator of the terminal effector phase of cell death/survival and is highly expressed in number of human cancers including MM, but not in normal adult human tissue. Transcription of survivin is modulated by Sp1 (39-43) and in pancreatic cancer cells, inhibition of Sp1 activity has been shown to decrease survivin expression and subsequently sensitize the cells to radiotherapy (43, 44).

The importance of Sp1 in myeloma is also supported by the recent observation that conventional and novel anti-MM drugs have direct effect on Sp1 activity. For example, it has been shown that HDAC1 could interact with Sp1 to regulate its activity (45) and HDAC inhibitors induce Sp1 activity (46) suggesting potential for synergism by using HDAC and Sp1 inhibitors together. Interestingly, Bortezomib has been shown to inhibit DNA–binding activity of Sp1 and disrupt the physical interaction of Sp1/NF-κB (47, 48). In MM, Bortezomib specifically down-regulates the expression of class I HDACs through caspase-8-dependent degradation of Sp1 protein (49). Having defined the cellular, signaling and the molecular mechanisms of sensitivity of MM to TMP, rationally designed combinations of conventional and novel agents to enhance cytotoxicity, to avoid or overcome drug resistance and to minimize adverse side effect profiles could be developed. More recently, it has been reported that both lenalidomide and pomalidomide upregulate Sp1 providing a rationale for their preclinical evaluation to increase cytotoxicity and overcome drug resistance (50).

In conclusion, we report significant role of Sp1 in myeloma cell growth and survival with its influence on clinical outcome in MM. Our preclinical in vitro and in vivo results suggest that specific inhibition of Sp1 activity may be an interesting potential therapeutic target alone and in combination with other agents in MM.
Acknowledgments.

This work was supported in part by DF/HCC myeloma SPORE Career Development Award to MF, grants from the Dept. of Veterans Affairs Merit Review Awards and from the National Institutes of Health Grants RO1-124929, and PO1-155249 to N.C.M., P50-100007 and PO1-78378 to NCM and KCA.

Author contributions: M.F. and N.C.M. designed research; M.F., P.N., and S.A. performed research; S.R. performed pathology; Y.T., R.P., S.M., P.T., T.H., C.L. and H.A. contributed reagents/analytic tools; M.F., K.C.A. and N.C.M analyzed data; M.F. and N.C.M wrote the manuscript.
References


22. Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia. 2007;9:406-17.


Figure Legends

**Figure 1. High Sp1 protein expression and activity in MM cells.** (A) Nuclear extracts from 8 MM cell lines were subjected to WB analysis using anti-Sp1 and p84 Abs. (B) Nuclear and cytoplasmic extracts from MM1S, U266 and PBMCs from 3 healthy donors were subjected to WB analysis using anti-Sp1 and GAPDH or p84 Abs. (C) 15 µg of nuclear proteins were analyzed for Sp1 activity using the Sp1 TF ELISA kit which measures Sp1 DNA binding activity. Absorbance was obtained with a spectrophotometer at 450 nm and presented as OD. (D) MM1S and U266 cells were transiently transfected with either negative control (NC)-luc or Sp1-promoter driven -Luc. After 48 h from transfection, MM cells were treated with 10 µM of U0126 or LY29004 or control for 30 minutes, washed and then cultured in absence (-) or presence (+) of BMSC for additional 6 h. The firefly luciferase activity was measured in cell lysate and normalized according to Renilla luciferase activity and expressed as relative luciferase units (RLU) to reflect the Sp1 promoter activity in the absence or presence of BMSC. The graph shows one representative experiment of two performed in triplicate. Results are shown as mean ± standard deviation.

**Figure 2. Sp1 knock-down decreases MM cell proliferation.** (A) U266 cells were transfected with TranSilent Human Sp1 siRNA. Cell lysates were obtained at indicated time and subjected to WB analysis to assess decrease in the Sp1 protein expression post-transfection using anti-Sp1 and GAPDH Abs. (B) The effect of Sp1 knockdown on Sp1 binding activity in MM cells transfected with Sp1 or control siRNA were was assessed by Sp1 TF ELISA and presented as proportional change from control cells. (C) The effect of Sp1 knockdown on cell proliferation in MM cells transfected with Sp1 or control siRNA was assessed by [3H]thymidine uptake, and presented as percentage of control cells. Data represent mean +/- SD of 3 independent
experiments performed in triplicate. (D) 48 hours post-transfection with Sp1 or control siRNA, the measurement of cell incorporated BrdU (with FITC anti-BrdU) and total DNA content (with 7-AAD) in U266 cells allowed for the discrimination of cell subsets that resided in G0/G1, S, or G2/M phases of the cell cycle. (E) OPM2 cells were transfected with TranSilent Human Sp1 siRNA. Cell lysates were obtained at indicated time and subjected to WB analysis (upper panel), and cell proliferation was assessed by [³H]thymidine uptake at the indicated post-transfection time. (F) MM1S cells were infected with either scrambled (sc) or 5 different Sp1 shRNA (sh#1, sh#2, sh#3, sh#4, sh#5). Cell lysates were subjected to WB with anti-Sp1 and GAPDH Abs (upper panel). The transfected cells were analyzed for Sp1 binding activity (line) and cell growth (columns) 24 h after the second transfection by Sp1 TF ELISA and [³H]thymidine uptake respectively. The results are presented as change from cells infected with scramble shRNA (lower panel). (G) U266 cells were infected with either scrambled (sc) or 3 different Sp1 shRNA (sh#2, sh#3, sh#5). Cell lysates were subjected to WB with anti-Sp1 and GAPDH Abs (upper panel), and cell proliferation was assessed 24 h after the second transfection by [³H]thymidine uptake. The results are presented as change from cells infected with scramble shRNA (lower panel).

**Figure 3. Inhibition of Sp1 binding and transcriptional activity correlates with MM cell growth arrest.** (A) U266 cells were cultured in the presence of 20 µM TMP for 24 hours (hrs) and nuclear extracts were subjected to Sp1 ELISA assay to assess Sp1 binding to its consensus sequence on the plate-bound oligonucleotide. (B) MM cells were transiently transfected with Sp1-Luc plasmid and 48 h post-transfection MM cell were cultured in absence (-) or presence (+) of BMSC and treated with placebo (C) or 20 µM of TMP (T) for additional 6 h. Luciferase activity was measured. Results are reported as mean of fold change from control (untreated cells). Mean values were calculated from five independent experiments and are shown as mean ± standard deviation. (C) U266 cells were treated with placebo or different concentrations of TMP (1-20 µM) for 24 h. Nuclear extracts were subjected to WB analysis using anti-Sp1 and p84 Abs to assess Sp1 protein levels. The ratio of Sp1 to p84 for each sample as assessed by densitometric quantitation of band intensity from WB is denoted. (D) Several MM cell lines were treated with various concentrations of TMP (1-20 µM) for 24 h and MM cell growth was assessed by [³H]thymidine uptake. Data are presented as % of vehicle-treated cell proliferation. (E) Primary CD138+ MM cells were cultured in the absence (-) or presence (+) of BMSC at different
concentration of TMP for 24 hours. Cell proliferation was assessed by \[^3\text{H}\]thymidine uptake, and expressed as cpm (count per minute). (F) BMSC from MM patients were treated with different concentration of TMP for 48 hours and cell proliferation was assessed by \[^3\text{H}\]thymidine uptake, and expressed as cpm.

**Figure 4. TMP induces apoptosis via caspase activation.** (A) Flow cytometric cell cycle analysis of BrdU incorporation was performed after treatment of cells with the inhibitor for 24 h. Data shown are percentage of cells in the different phases of the cell cycle. (B) MM1S were cultured in the absence or presence of TMP and apoptotic cell death was assessed by flow cytometric analysis following AnnexinV and propidium iodide staining. In the upper panel it is shown the % of AnnexinV+/PI- (early apoptosis) and AnnexinV+/PI+ (late apoptosis) cells at the indicated time, while a representative experiment (48 hours post treatment) is shown in the lower panel. (C) Whole cell lysate from MM1S cells treated with TMP (10\(\mu\)M) for the indicated time periods was subjected to Western blot analysis and probed with antibodies against caspases 3, 8, 9, 7, PARP, Survivin, cdc2 with GAPDH as loading control.

**Figure 5. TMP inhibits MM cell growth and prolongs survival in vivo.** (A) U266, OPM2 and MM1S cells were injected s.c. in 3 different cohorts of SCID mice. Following detection of tumor, mice were treated with either 2 mg TMP or placebo s.c. daily for 3 weeks. Tumors were measured in two perpendicular dimensions once every 3 days. (B) Survival was evaluated from the first day of treatment until death using the Graphpad analysis software. (C) Tumors were isolated from TMP-treated and control mice and sections were evaluated by histological examinations following Ki67 staining showing decreased proliferation; caspase3 and TUNEL stains showing significant tumor cell apoptosis. (D) Evaluation of survivin levels was performed in the paraffin embedded tumor sections stained with a combination of primary antibodies specific for CD138 and survivin. The tissue sections were imaged and the relative amount of survivin localized within tumor-cell nuclear compartment was determined using Automated quantitation of antigen expression (AQUA) analysis. The data reflects the results of 12 fields imaged at 200x magnification per tumor. (E) In the SCID-hu model, mice, at the first detection of tumor, were treated with vehicle (n=3) or TMP (n=3). Serum samples were collected weekly and level of shuIL-6R was measured by ELISA as a marker of tumor growth. Baseline values before treatment were not significantly different among groups.
Supplemental Figure 1. (A) MM1S cells were treated with placebo or different concentrations of TMP (1-20 μM) for 24 h. Nuclear extracts were subjected to WB analysis using anti-Sp1 and p84 Abs to assess Sp1 protein levels. The ratio of Sp1 to p84 for each sample as assessed by densitometric quantitation of band intensity from WB is denoted. (B) MM1S cells were treated with placebo or 20 μM TMP for the indicated time periods and nuclear extracts subjected to WB analysis using indicated Abs.

Supplemental Figure 2. MM1S and U266 cells were incubated in the presence or absence of TMP for 6 h. After the culture period, the conditioned media were collected and VEGF levels were measured by ELISA assay. Data are presented as fold change inhibition of VEGF production as compared with the control culture. Values are means +/- SD from 3 independent experiments.
**FIGURE 1**

(A) MM CELL LINES

- **Cytoplasmic**
  - MM1S, U266, OPM1, OPM2, INA6, LR5, RPMI, 12BM
- **Nuclear**
  - MM1S, U266

(B) MM CELL LINES

- **Cytoplasmic**
  - MM1S, U266
- **Nuclear**
  - MM1S, U266

(C) OD

- MM cell lines
- PBMC
- BMSC

(D) RLU

- **MM1S**
  - OD: 0, 0, U0126, LY29004
- **U266**
  - OD: 0, 0, U0126, LY29004

*p* = 0.008

*p* = 0.02

+ BMSC
FIGURE 3

Panel A: Bar graph showing the Sp1 binding activity over time for MM1S and U266 cell lines.

Panel B: Histogram comparing the fold change of cell count between MM1S and U266 under different conditions.

Panel C: Table listing the TMP (µM) concentrations along with Sp1 (95 kDa) and p84 levels.

Panel D: Graph depicting the % of cell proliferation with varying TMP dose (µM) across different cell lines.

Panel E: Graph showing cpm levels with BMSC and varying TMP dose (µM) for MM1S, MM1R, OPM1, RPMI, LR5, KMS12BM, H929, MM1S, L363, INA-6, XG1, XG2, and OPM2.

Panel F: Bar graph displaying cpm levels with varying TMP dose (µM) for different cell lines.

Legend:
- H929
- MM1R
- OPM1
- RPMI
- LR5
- KMS12BM
- MM1S
- L363
- INA-6
- XG1
- XG2
- OPM2

Note: All data points are presented as mean ± standard error of the mean (SEM).
**FIGURE 4**

A. Flow cytometry analysis of DNA content and apoptosis using BrdU and 7-ADD stains. The graphs show the percentage of cells in G1, S, and G2/M phases for CNT and TR treatments.

B. Bar graph showing the percentage of early and late apoptosis in cells treated with different TMP doses. The graph includes data for CNT and 10 µM TMP.

C. Western blot analysis of caspases and apoptosis-related proteins. The blots show the expression levels of Caspase 9-FL, Caspase 9-FC, Caspase 8-FL, Caspase 3-FL, Caspase 3-FC, Caspase 7-FL, Caspase 7-FC, PARP-FL, PARP-FC, Survivin, and GAPDH at different time points (0, 24, 48, 72 hours).
FIGURE 5

A) Tumor Volume (mm³)

B) Percent survival

C) H&E, Ki67, Tunel, Caspase 3

D) Acqua Score

E) Placebo vs TMP (50 mg/Kg)

Days from tumor detection and treatment
Clinical Cancer Research

Significant biological role of Sp1 transactivation in multiple myeloma

Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, et al.

Clin Cancer Res  Published OnlineFirst August 19, 2011.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-11-1036

Supplementary Material  Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2011/08/19/1078-0432.CCR-11-1036.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.